Menu
Menu
Shilpa Medicare has achieved a significant milestone with its Unit IV and Unit VII receiving GMP approval from the Eurasian Economic Union. This certification opens up new business opportunities in key markets like Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia, reinforcing the company’s commitment to delivering high-quality pharmaceutical products globally.